Stereotactic radiotherapy and cytokines: preliminary analysis in oligometastatic Non-Small-Cell lung cancer

Borghetti, P.; Guerini, A.E.; Colosini, A.; Facheris, G.; Gandolfo, C.; Triggiani, L.; Bruni, A.; D’Angelo, E.; Grazia Cusi, M.; Magrini, S.M.; Bresciani, R.; Nardone, V.

doi:10.52547/ijrr.21.2.10

[Home ] [Archive]

International Journal of Radiation Research

Main Menu

Home

IJRR Information

For Authors

For Reviewers

Subscription

News & Events

Web Mail

Search in website

Receive site information

ISSN

Hard Copy 2322-3243

Online 2345-4229

Online Submission

Now you can send your articles to IJRR office using the article submission system.

Volume 21, Issue 2 (4-2023) Int J Radiat Res 2023, 21(2): 247-254 | Back to browse issues page

‎ 10.52547/ijrr.21.2.10

Mendeley

Zotero

RefWorks

Borghetti P, Guerini A, Colosini A, Facheris G, Gandolfo C, Triggiani L, et al . Stereotactic radiotherapy and cytokines: preliminary analysis in oligometastatic Non-Small-Cell lung cancer. Int J Radiat Res 2023; 21 (2) :247-254
URL: http://ijrr.com/article-1-4720-en.html

Stereotactic radiotherapy and cytokines: preliminary analysis in oligometastatic Non-Small-Cell lung cancer

P. Borghetti

, G. Facheris

, A. Bruni

Department of Radiation Oncology, University and Spedali Civili Hospital of Brescia, P.le Spedali Civili 1, 25123 Brescia, Italy

Abstract: (1534 Views)

Background: Cytokines have a recognized role in the physiopathology of cancer disease and could be involved also in the “abscopal effect”. Aim of this work is the preliminary analysis of inflammatory mediators in patients with oligometastatic non-small-cell lung cancer (NSCLC) undergoing stereotactic radiotherapy (SRT). Materials and Methods: This was a feasibility multi-institutional study that prospectively included oligometastatic NSCLC patients undergoing SRT from June 2018 until August 2018 and healthy controls. Blood samples were collected at three different time points (1-5 days before SRT, 1-5 days after SRT and 28-35 days after SRT). A commercially available kit was used for quantitative analysis of 44 inflammation molecules. Nine patients and four healthy controls were enrolled. Results: Several cytokines (54.5%) resulted undetectable in a significant percentage of the samples and were not further analyzed. Levels of seven inflammatory molecules (bDNF, MIP-1b, PDGF-bb, PIGF-1, RANTES, SDF1-a, and bNGF) showed significant variations after SRT in the NSCLC patients cohort. Conclusion: Significant plasmatic concentration changes after SRT were reported for a relevant proportion of the evaluated molecules. The results of this study will contribute to define a selection of cytokines and chemokines that will be analyzed in a prospective trial with a larger sample of patients.

Keywords: Stereotactic radiotherapy, cytokines, oligometastatic, lung cancer.

Full-Text [PDF 646 kb] (856 Downloads)

Type of Study: Original Research | Subject: Radiation Biology

References

1. Buglione M, Jereczek-Fossa BA, et al. (2020) Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent. Lung Cancer, 141: 1-8. [DOI:10.1016/j.lungcan.2019.12.019] [PMID]

2. Ricardi U, Frezza G, et al. (2014) Stereotactic ablative radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer, 84: 248-53. [DOI:10.1016/j.lungcan.2014.02.015] [PMID]

3. Macià i Garau M (2017) Radiobiology of stereotactic body radiation therapy (SBRT). Rep Pract Oncol Radiother, 22(2): 86-95. [DOI:10.1016/j.rpor.2017.02.010] [PMID] []

4. Finkelstein SE and Timmerman R (2011) The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol, 439752. [DOI:10.1155/2011/439752] [PMID] []

5. Reynders K, Illidge T, et al. (2015) The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev, 41(6): 503-10. [DOI:10.1016/j.ctrv.2015.03.011] [PMID] []

6. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer, 4(1): 11-22. [DOI:10.1038/nrc1252] [PMID]

7. Bhalla N, Brooker R, et al. (2018) Combining immunotherapy and radiotherapy in lung cancer. J Thorac Dis, 10(13): S1447-S1460. [DOI:10.21037/jtd.2018.05.107] [PMID] []

8. Liu S, Sun X, et al. (2015) Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res, 5(11): 3276-3285.

9. Lhuillier C, Rudqvist NP, et al. (2019) Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med, 11(1): 40. [DOI:10.1186/s13073-019-0653-7] [PMID] []

10. Apetoh L, Ghiringhelli F, et al. (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy; NatureMedicine, 13(9): 1050-1059.

11. Ngwa W, Irabor OC, et al. (2018) Using immunotherapy to boost the abscopal effect. Nat Rev Cancer, 18(5): 313-322. [DOI:10.1038/nrc.2018.6] [PMID] []

12. Bernstein MB and Krishnan S, et al. (2016) Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol, 13: 516-524. [DOI:10.1038/nrclinonc.2016.30] [PMID] []

13. Yilmaz MT, Elmali A, et al. (2019) Abscopal effect, from myth to reality: From radiation oncologists' perspective. Cureus, 11(1): e3860. [DOI:10.7759/cureus.3860] [PMID] []

14. Marconi R, Strolin S, et al. (2017) A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? PLoS One, 12(2): e0171559. [DOI:10.1371/journal.pone.0171559] [PMID] []

15. Dewan MZ, Galloway AE, et al. (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res, 15: 5379-88. [DOI:10.1158/1078-0432.CCR-09-0265] [PMID] []

16. Demaria S, Formenti SC, et al. (2012) Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol, 2: 153. [DOI:10.3389/fonc.2012.00153] [PMID] []

17. Borghetti P, Bonù ML, et al. (2019) Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiol Med, 124(7): 662-670. [DOI:10.1007/s11547-019-00999-w] [PMID]

18. Borghetti P, Bonù ML, et al. (2018) Radiotherapy and tyrosine kinase inhibitors in stage IV non-small cell lung cancer: Real-life experience. In Vivo, 32(1): 159-164. [DOI:10.21873/invivo.11219]

19. Martinez P, Peters S, et al. (2019) Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer. Clin Cancer Res, 25(9): 2691-2698. [DOI:10.1158/1078-0432.CCR-18-3904] [PMID]

20. Kim W, Lee S, et al. (2019) Cellular stress responses in radiotherapy. Cells, 8(9): 1105. [DOI:10.3390/cells8091105] [PMID] []

21. Bubici C and Papa S, et al. (2006) Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene, 25(51): 6731-48. [DOI:10.1038/sj.onc.1209936] [PMID]

22. Shakibaei M, Schulze-Tanzil G, et al. (2005) Redox regulation of apoptosis by members of the TNF superfamily. Antioxid Redox Signal, 7(3-4): 482-96. [DOI:10.1089/ars.2005.7.482] [PMID]

23. Chen Y, Williams J, et al. (2002) Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol, 12(1 - 1): 26-33. [DOI:10.1053/srao.2002.31360] [PMID]

24. Lierova A, Jelicova M, et al. (2018) Cytokines and radiation-induced pulmonary injuries. J Radiat Res, 59(6): 709-753. [DOI:10.1093/jrr/rry067] [PMID] []

25. Silva EM, Mariano VS, et al. (2017) High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer. PLoS One, 12(7): e0181125. [DOI:10.1371/journal.pone.0181125] [PMID] []

26. De Vita F, Orditura M, et al. (2000) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest, 117: 365-73. [DOI:10.1378/chest.117.2.365] [PMID]

27. Wang S, Chen J, et al. (2015) Prognostic value of cytokine profile on survival in non-small cell lung cancer patients treated with radiotherapy. Journal of Clinical Oncology, 33: 15_suppl, 7525-7525. [DOI:10.1200/jco.2015.33.15_suppl.7525]

28. Trovo M, Giaj-Levra N, et al. (2016) Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study. Clin Transl Oncol, 18(10): 1003-10. [DOI:10.1007/s12094-015-1473-x] [PMID]

29. Zhang T, Yu H, et al. (2017) Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer. Sci Rep, 7(1): 4866. [DOI:10.1038/s41598-017-04978-x] [PMID] []

30. Ellsworth SG, Rabatic BM, et al. (2017) Principal component analysis identifies patterns of cytokine expression in non-small cell lung cancer patients undergoing definitive radiation therapy. PLoS One, 12(9): e0183239. [DOI:10.1371/journal.pone.0183239] [PMID] []

31. McGee HM, Daly ME, et al. (2018) Stereotactic ablative radiation therapy induces systemic differences in peripheral blood immunophenotype dependent on irradiated site. Int J Radiat Oncol Biol Phys, 101(5): 1259-1270. [DOI:10.1016/j.ijrobp.2018.04.038] [PMID] []

32. Radin DP, Patel P, et al. (2017) BDNF: An oncogene or tumor suppressor? Anticancer Res, 37(8): 3983-3990. [DOI:10.21873/anticanres.11783]

33. Calabrese F, Rossetti AC, et al. (2014) Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci, 8: 430. [DOI:10.3389/fncel.2014.00430] [PMID] []

34. Luo X, Yu Y, et al. (2004) Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells. Cell Mol Immunol, 1(3): 199-204.

35. Li L, Liu YD, et al. (2018) High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma. Thorac Cancer, 9(7): 775-784. [DOI:10.1111/1759-7714.12643] [PMID] []

36. Aldinucci D, Colombatti A, et al. (2019) The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm, 2014: 292376. [DOI:10.1155/2014/292376] [PMID] []

37. Zhou W, Guo S, et al. (2019) Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. Curr Med Chem, 26(17): 3026-3041. [DOI:10.2174/0929867324666170830111531] [PMID] []

38. Barinov A, Luo L, et al. (2017) Essential role of immobilized chemokine CXCL12 in the regulation of the humoral immune response. USA. Proc Natl Acad Sci, 114(9): 2319-2324. [DOI:10.1073/pnas.1611958114] [PMID] []

39. Zhang N, Hu H, et al. (2018) The overexpression of PDGF-BB and its receptor is correlated with lymphatic metastasis in patients with non-small cell lung cancer. Int J Clin Exp Pathol, 11(12): 6010-6017.

40. Albonici L, Giganti MG, et al. (2019) Multifaceted role of the placental growth factor (PlGF) in the antitumor immune response and cancer progression. Int J Mol Sci, 20(12). [DOI:10.3390/ijms20122970] [PMID] []

41. Kiang JG, Smith JT, et al. (2018) Circulating cytokine/chemokine concentrations respond to ionizing radiation doses but not radiation dose rates: Granulocyte-colony stimulating factor and interleukin-18. Radiat Res, 189(6): 634-643. [DOI:10.1667/RR14966.1] [PMID] []

42. Willett CG, Duda DG, et al. (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol, 27(18): 3020-6. [DOI:10.1200/JCO.2008.21.1771] [PMID] []

43. Aloe L, Rocco ML, et al. (2016) Nerve growth factor: role in growth, differentiation and controlling cancer cell development. J Exp Clin Cancer Res, 35: 116. [DOI:10.1186/s13046-016-0395-y] [PMID] []

44. Burgos-Ramos E and Martos-Moreno G (2012) Multiplexed bead immunoassays: Advantages and limitations in pediatrics. Advances in Immunoassay Technology. 2012; DOI: 10.5772/36024 [DOI:10.5772/36024]

45. de Jager W, Bourcier K , et al. (2009) Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol, 10: 52. [DOI:10.1186/1471-2172-10-52] [PMID] []

46. Tighe PJ, Ryder RR, et al. (2015) ELISA in the multiplex era: potentials and pitfalls. Proteomics Clin Appl, 9(3-4): 406-22. 10.1002/prca.201400130. [DOI:10.1002/prca.201400130] [PMID] []

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Persian site map - English site map - Created in 0.05 seconds with 48 queries by YEKTAWEB 4722